Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer - Poll - MDSpire

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

  • By

  • Yu Xia

  • Jiawei Song

  • Haiyan Zhang

  • Shiwei Liu

  • Jing Luo

  • July 17, 2026

Share

Original Source(s)

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

  • by Yu Xia, Jiawei Song, Haiyan Zhang, Shiwei Liu, Jing Luo

  • July 17, 2026

Related Content

Perioperative substance P/NK1R pharmacology: from PONV control to a testable cancer neuro-immune hypothesis

Factors associated with breast self-examination practice among female medical students in selected universities in Borama, Somaliland

Multi-scale information bottleneck with confidence-weighted decision fusion for robust breast ultrasound lesion classification